Shen-Liang Shih
Overview
Explore the profile of Shen-Liang Shih including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
77
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kan J, Shih S, Yang S, Chu P, Chen F, Li C, et al.
Int J Mol Sci
. 2024 Jan;
25(2).
PMID: 38279296
Exosomal microRNAs (miRNAs) are novel, non-invasive biomarkers for facilitating communication and diagnosing cancer. However, only a few studies have investigated their function and role in the clinical diagnosis of breast...
2.
Wu C, Pan M, Shih S, Shiau J, Wu C, Chang S, et al.
Biomed Pharmacother
. 2023 May;
163:114732.
PMID: 37254289
Triple-negative breast cancer (TNBC) is characterized by the loss of expression of several biomarkers, which limits treatment strategies for the disease. In recent years, immunotherapy has shown promising results in...
3.
Huang C, Wu C, Hsu W, Shih S
Radiol Case Rep
. 2023 Apr;
18(6):2145-2148.
PMID: 37089966
The most common metastatic sites in breast cancer include the liver, bone, the lungs, and the brain. Metastasis to the gastrointestinal system is rare and can occur years after breast...
4.
Chiu C, Chang L, Su C, Shih S, Tam K
Surg Oncol
. 2022 Nov;
45:101880.
PMID: 36332555
Purpose: Although ductal carcinoma in situ (DCIS) seldom involves lymph nodes, some patients may upstage to invasive disease, thus requiring a second surgery for sentinel lymph node (SLN) biopsy (SLNB)....
5.
Li C, Moi S, Lin H, Hou M, Chen F, Shih S, et al.
Int J Mol Sci
. 2022 Sep;
23(18).
PMID: 36142451
Endocrine therapy (ET) of selective estrogen receptor modulators (SERMs), selective estrogen receptor downregulators (SERDs), and aromatase inhibitors (AIs) has been used as the gold standard treatment for hormone-receptor-positive (HR+) breast...
6.
Huang C, Kuo Y, Chen Y, Shih S
Medicine (Baltimore)
. 2022 Aug;
101(32):e29607.
PMID: 35960130
Introduction: There has been an ongoing debate about the benefits and risks between synchronous surgery and two independent surgery of ovary tumor removal and breast reconstruction. Here we report a...
7.
Chen Y, Tu Y, Chen H, Shih S
Int J Surg Case Rep
. 2022 Feb;
91:106804.
PMID: 35131627
Introduction And Importance: Phyllodes tumors (PT) account for approximately 1% of all breast tumors. The coexistence of phyllodes tumor and invasive lobular carcinoma in the ipsilateral breast is extremely rare...
8.
Shiau J, Wu C, Chang S, Pan M, Liu W, Ou-Yang F, et al.
Biomedicines
. 2021 Dec;
9(12).
PMID: 34944605
Triple-negative breast cancer (TNBC) remains a significant clinical challenge because of its high vascularity and metastatic and recurrent rates. Tumor angiogenesis is considered an important mediator in the regulation of...
9.
Hou M, Ou-Yang F, Li C, Chen F, Chuang C, Kan J, et al.
Exp Mol Med
. 2021 Oct;
53(10):1636-1646.
PMID: 34707191
In Western countries, breast cancer tends to occur in older postmenopausal women. However, in Asian countries, the proportion of younger premenopausal breast cancer patients is increasing. Increasing evidence suggests that...
10.
Lin J, Su J, Fu T, Shih S
Radiol Case Rep
. 2021 Sep;
16(11):3383-3388.
PMID: 34504630
Locally advanced breast cancer (LABC) is generally treated with combined-modality therapy including systemic chemotherapy, surgery, radiotherapy, and targeted therapy due to its nature of rapid onset of metastatic disease and...